Abstract
Background
Extracellular matrix (ECM) degradation, chondrocyte inflammation, and
cellular senescence contribute to the pathology of osteoarthritis (OA).
Empagliflozin, a selective inhibitor of sodium-glucose cotransporter-2
(SGLT2), has been reported to show the anti-inflammatory properties in
several conditions. However, whether empagliflozin can be used to
improve OA is still unknown.